PMC:7461420 / 79434-79903 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T371","span":{"begin":0,"end":3},"obj":"Disease"},{"id":"T372","span":{"begin":82,"end":86},"obj":"Disease"},{"id":"T373","span":{"begin":273,"end":277},"obj":"Disease"},{"id":"T374","span":{"begin":337,"end":341},"obj":"Disease"}],"attributes":[{"id":"A371","pred":"mondo_id","subj":"T371","obj":"http://purl.obolibrary.org/obo/MONDO_0011549"},{"id":"A372","pred":"mondo_id","subj":"T372","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A373","pred":"mondo_id","subj":"T373","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A374","pred":"mondo_id","subj":"T374","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"HTS of a chemical library of 25000 molecules identified 170 (Figure 37) as a dual SARS‐CoV‐1 PLpro (IC50, 10.9 µM) and MERS‐CoV PLpro (IC50, 6.2 µM) inhibitor. 200 This compound acts via competitive inhibition against MERS‐CoV PLpro, yet via allosteric inhibition against SARS‐CoV‐1 PLpro. This compound also exhibited a preference for SARS‐CoV‐1 PLpro and MERS‐CoV PLpro versus two human homologs of the PLpro, ubiquitin C‐terminal hydrolase, (hUCH‐L1) and (hUCH‐L3)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T941","span":{"begin":7,"end":8},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T942","span":{"begin":75,"end":76},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T943","span":{"begin":320,"end":321},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T944","span":{"begin":384,"end":389},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"}],"text":"HTS of a chemical library of 25000 molecules identified 170 (Figure 37) as a dual SARS‐CoV‐1 PLpro (IC50, 10.9 µM) and MERS‐CoV PLpro (IC50, 6.2 µM) inhibitor. 200 This compound acts via competitive inhibition against MERS‐CoV PLpro, yet via allosteric inhibition against SARS‐CoV‐1 PLpro. This compound also exhibited a preference for SARS‐CoV‐1 PLpro and MERS‐CoV PLpro versus two human homologs of the PLpro, ubiquitin C‐terminal hydrolase, (hUCH‐L1) and (hUCH‐L3)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T85927","span":{"begin":35,"end":44},"obj":"Chemical"},{"id":"T90186","span":{"begin":149,"end":158},"obj":"Chemical"}],"attributes":[{"id":"A53594","pred":"chebi_id","subj":"T85927","obj":"http://purl.obolibrary.org/obo/CHEBI_25367"},{"id":"A39348","pred":"chebi_id","subj":"T90186","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"HTS of a chemical library of 25000 molecules identified 170 (Figure 37) as a dual SARS‐CoV‐1 PLpro (IC50, 10.9 µM) and MERS‐CoV PLpro (IC50, 6.2 µM) inhibitor. 200 This compound acts via competitive inhibition against MERS‐CoV PLpro, yet via allosteric inhibition against SARS‐CoV‐1 PLpro. This compound also exhibited a preference for SARS‐CoV‐1 PLpro and MERS‐CoV PLpro versus two human homologs of the PLpro, ubiquitin C‐terminal hydrolase, (hUCH‐L1) and (hUCH‐L3)."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T75","span":{"begin":413,"end":443},"obj":"http://purl.obolibrary.org/obo/GO_0004843"}],"text":"HTS of a chemical library of 25000 molecules identified 170 (Figure 37) as a dual SARS‐CoV‐1 PLpro (IC50, 10.9 µM) and MERS‐CoV PLpro (IC50, 6.2 µM) inhibitor. 200 This compound acts via competitive inhibition against MERS‐CoV PLpro, yet via allosteric inhibition against SARS‐CoV‐1 PLpro. This compound also exhibited a preference for SARS‐CoV‐1 PLpro and MERS‐CoV PLpro versus two human homologs of the PLpro, ubiquitin C‐terminal hydrolase, (hUCH‐L1) and (hUCH‐L3)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2452","span":{"begin":413,"end":443},"obj":"Gene"},{"id":"2453","span":{"begin":446,"end":453},"obj":"Gene"},{"id":"2454","span":{"begin":460,"end":467},"obj":"Gene"},{"id":"2455","span":{"begin":82,"end":90},"obj":"Species"},{"id":"2456","span":{"begin":119,"end":127},"obj":"Species"},{"id":"2457","span":{"begin":219,"end":227},"obj":"Species"},{"id":"2458","span":{"begin":273,"end":281},"obj":"Species"},{"id":"2459","span":{"begin":337,"end":345},"obj":"Species"},{"id":"2460","span":{"begin":358,"end":366},"obj":"Species"},{"id":"2461","span":{"begin":384,"end":389},"obj":"Species"}],"attributes":[{"id":"A2452","pred":"tao:has_database_id","subj":"2452","obj":"Gene:7345"},{"id":"A2453","pred":"tao:has_database_id","subj":"2453","obj":"Gene:7345"},{"id":"A2454","pred":"tao:has_database_id","subj":"2454","obj":"Gene:7347"},{"id":"A2455","pred":"tao:has_database_id","subj":"2455","obj":"Tax:694009"},{"id":"A2456","pred":"tao:has_database_id","subj":"2456","obj":"Tax:1335626"},{"id":"A2457","pred":"tao:has_database_id","subj":"2457","obj":"Tax:1335626"},{"id":"A2458","pred":"tao:has_database_id","subj":"2458","obj":"Tax:694009"},{"id":"A2459","pred":"tao:has_database_id","subj":"2459","obj":"Tax:694009"},{"id":"A2460","pred":"tao:has_database_id","subj":"2460","obj":"Tax:1335626"},{"id":"A2461","pred":"tao:has_database_id","subj":"2461","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"HTS of a chemical library of 25000 molecules identified 170 (Figure 37) as a dual SARS‐CoV‐1 PLpro (IC50, 10.9 µM) and MERS‐CoV PLpro (IC50, 6.2 µM) inhibitor. 200 This compound acts via competitive inhibition against MERS‐CoV PLpro, yet via allosteric inhibition against SARS‐CoV‐1 PLpro. This compound also exhibited a preference for SARS‐CoV‐1 PLpro and MERS‐CoV PLpro versus two human homologs of the PLpro, ubiquitin C‐terminal hydrolase, (hUCH‐L1) and (hUCH‐L3)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T686","span":{"begin":0,"end":159},"obj":"Sentence"},{"id":"T687","span":{"begin":160,"end":290},"obj":"Sentence"},{"id":"T688","span":{"begin":291,"end":469},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"HTS of a chemical library of 25000 molecules identified 170 (Figure 37) as a dual SARS‐CoV‐1 PLpro (IC50, 10.9 µM) and MERS‐CoV PLpro (IC50, 6.2 µM) inhibitor. 200 This compound acts via competitive inhibition against MERS‐CoV PLpro, yet via allosteric inhibition against SARS‐CoV‐1 PLpro. This compound also exhibited a preference for SARS‐CoV‐1 PLpro and MERS‐CoV PLpro versus two human homologs of the PLpro, ubiquitin C‐terminal hydrolase, (hUCH‐L1) and (hUCH‐L3)."}